Rina-S is named as a drug or biological intervention in 7 clinical trials in our USA and China trial registers, 6 of which are recruiting. The lead sponsor is Genmab. Registered phases: Phase 3, Phase 2 and Phase 1/2. Conditions studied include Ovarian Cancer; Platinum-resistant Ovarian Cancer; Endometrial Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Ovarian Cancer | 2 |
| Platinum-resistant Ovarian Cancer | 2 |
| Endometrial Cancer | 1 |
| Recurrent or Progressive Endometrial Cancer | 1 |
| Platinum-Sensitive Ovarian Cancer | 1 |
| Platinum-sensitive Ovarian Cancer | 1 |
| PSOC | 1 |
| Non-small Cell Lung Cancer (NSCLC) | 1 |
| High Grade Epithelial Ovarian Cancer | 1 |
| High Grade Serous Ovarian Cancer | 1 |
| Primary Peritoneal Carcinoma | 1 |
| Fallopian Tube Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Genmab | 7 |
| Register | Rina-S trials |
|---|---|
| Clinical trials in USA | 6 |
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rina-S works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rina-S (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.